Arcturus Therapeutics Holdings Inc. (ARCT)

CTI BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-80.94	-29.73	9.35	-203.67	-72.15
Depreciation & Amortization	3.54	2.96	1.53	1.19	0.88
Asset Writedown & Restructuring Costs	-	-	-	5	-
Loss (Gain) on Equity Investments	-	-	0.52	-0.52	0.26
Stock-Based Compensation	37.99	34.65	30.61	28.92	6.76
Other Operating Activities	0.47	-33.36	2.55	1.41	0.16
Change in Accounts Receivable	28.09	-29.3	0.6	-1.24	0.05
Change in Accounts Payable	1.92	-2.24	-3.11	-0.77	4.81
Change in Unearned Revenue	-55.21	38.61	-14.69	32.79	7.04
Change in Other Net Operating Assets	4.39	0.31	4.65	1.84	9.31
Operating Cash Flow	-59.75	-18.1	31.99	-135.04	-42.86
Capital Expenditures	-0.65	-2.9	-7.73	-3.41	-1.74
Investing Cash Flow	-0.65	-2.9	-7.73	-3.41	-1.74
Long-Term Debt Issued	-	20	-	46.6	-
Long-Term Debt Repaid	-	-47.36	-5	-	-
Net Debt Issued (Repaid)	-	-27.36	-5	46.6	-
Issuance of Common Stock	5.42	3.28	2.14	1.42	436.15
Financing Cash Flow	5.42	-24.09	-2.86	48.02	436.15
Net Cash Flow	-54.98	-45.09	21.41	-90.43	391.54
Free Cash Flow	-60.4	-21	24.27	-138.45	-44.6
Free Cash Flow Margin	-39.65%	-12.59%	11.78%	-1120.23%	-467.59%
Free Cash Flow Per Share	-2.24	-0.79	0.90	-5.26	-2.20
Cash Interest Paid	-	2.13	0.81	0.68	0.75
Cash Income Tax Paid	1.41	-	-	-	-
Levered Free Cash Flow	-9.02	-82.55	15.96	-74.77	-15.13
Unlevered Free Cash Flow	-9.02	-82.07	15.96	-74.77	-14.61
Change in Working Capital	-20.81	7.38	-12.56	32.63	21.22

Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q